Tag results:

clinical trial

Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase II Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients with...

[Imbria Pharmaceuticals] Imbria Pharmaceuticals announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the IMPROVE-HCM study, a Phase II study of the safety, tolerability, and efficacy of IMB-101 in patients with non-obstructive hypertrophic cardiomyopathy.

Up-Front Carfilzomib, Lenalidomide, and Dexamethasone with Transplant for Patients with Multiple Myeloma: The IFM KRd Final Results

[Blood] In this Phase II study, patients received eight 28-day cycles of carfilzomib (K), lenalidomide (R), and dexamethasone (d). All patients proceeded to transplant after four cycles and received one year of lenalidomide maintenance. The eight cycles of KRd produced fast and deep responses in transplant-eligible patients with newly diagnosed multiple myeloma.

Corvus Pharmaceuticals Discontinues Phase III Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

[Corvus Pharmaceuticals, Inc.] Corvus Pharmaceuticals, Inc. announced that it has discontinued its Phase III study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering serious infection and hospitalizations.

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

[BriaCell Therapeutics, Corp.] BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announced the open recruitment and enrollment of their collaborative clinical study with Incyte for the treatment of advanced breast cancer.

Immunologic Mechanisms of Seasonal Influenza Vaccination Administered by Microneedle Patch from a Randomized Phase I Trial

[NPJ Vaccines] Investigators compared the humoral and cellular immunologic responses in a subset of participants receiving influenza vaccination by microneedle patches to the intramuscular route of administration.

INmune Bio, Inc. Announces First Patient Treated with NK Cell Priming “Pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

[INmune Bio, Inc.] INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase I clinical trial of its Natural Killer cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome.

Popular